[go: up one dir, main page]

MX2015008032A - Una composicion farmaceutica que contiene candesartan cilexetilo y amlodipina. - Google Patents

Una composicion farmaceutica que contiene candesartan cilexetilo y amlodipina.

Info

Publication number
MX2015008032A
MX2015008032A MX2015008032A MX2015008032A MX2015008032A MX 2015008032 A MX2015008032 A MX 2015008032A MX 2015008032 A MX2015008032 A MX 2015008032A MX 2015008032 A MX2015008032 A MX 2015008032A MX 2015008032 A MX2015008032 A MX 2015008032A
Authority
MX
Mexico
Prior art keywords
composition
pharmaceutical composition
cilexetilo
amlodipina
composition containing
Prior art date
Application number
MX2015008032A
Other languages
English (en)
Other versions
MX374106B (es
Inventor
Agnieszka Cieplucha
Original Assignee
Adamed Sp Zoo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030379&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015008032(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adamed Sp Zoo filed Critical Adamed Sp Zoo
Publication of MX2015008032A publication Critical patent/MX2015008032A/es
Publication of MX374106B publication Critical patent/MX374106B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición farmacéutica de combinación que comprende candesartán cilexetilo y amlodipina o una sal farmacéuticamente aceptable de la misma, un procedimiento para la preparación de dicha composición y una forma de dosificación unitaria que comprende dicha composición; la composición consiste en una granulado que contiene candesartán cilexetilo, polietilenglicol y otros excipientes, en donde la relación en peso de candesartán cilexetilo a polietilenglicol está en la escala de 5:1 a 2:1, y fase extragranular de la mezcla en polvo que comprende amlodipina o una sal farmacéuticamente aceptable de la misma y excipientes; la composición se prepara al mezclar el granulado preparado por granulación en húmedo y la fase extragranular.
MX2015008032A 2012-12-21 2013-12-19 Una composicion farmaceutica que contiene candesartan cilexetilo y amlodipina. MX374106B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL402191A PL236001B1 (pl) 2012-12-21 2012-12-21 Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję
PCT/IB2013/061138 WO2014097209A1 (en) 2012-12-21 2013-12-19 A pharmaceutical composition containing candesartan cilexetil and amlodipine

Publications (2)

Publication Number Publication Date
MX2015008032A true MX2015008032A (es) 2015-10-30
MX374106B MX374106B (es) 2025-03-05

Family

ID=50030379

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008032A MX374106B (es) 2012-12-21 2013-12-19 Una composicion farmaceutica que contiene candesartan cilexetilo y amlodipina.

Country Status (18)

Country Link
EP (1) EP2934488B1 (es)
AU (1) AU2013365715B2 (es)
BR (1) BR112015014875A2 (es)
EA (1) EA030704B1 (es)
ES (1) ES2706067T3 (es)
HR (1) HRP20190049T1 (es)
HU (1) HUE042194T2 (es)
MX (1) MX374106B (es)
MY (1) MY185947A (es)
PH (1) PH12015501301A1 (es)
PL (2) PL236001B1 (es)
PT (1) PT2934488T (es)
RS (1) RS58214B1 (es)
SG (1) SG11201504473XA (es)
TR (1) TR201900350T4 (es)
UA (1) UA115257C2 (es)
WO (1) WO2014097209A1 (es)
ZA (1) ZA201505192B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016102705A1 (en) * 2014-12-24 2016-06-30 Krka, D.D., Novo Mesto Pharmaceutical composition comprising candesartan or pharmaceutically acceptable salts or esters thereof and amlodipine or pharmaceutically acceptable salts thereof
CN104721159A (zh) * 2015-03-24 2015-06-24 浙江康乐药业股份有限公司 一种苯磺酸氨氯地平片及其制备方法
KR101710441B1 (ko) * 2015-12-28 2017-02-28 신풍제약주식회사 안정성 및 용출성이 향상된 정제
EP3219309A1 (en) * 2016-03-17 2017-09-20 K.H.S. Pharma Holding GmbH Fixed dosed pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension
US10350171B2 (en) * 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same
EP4374855A1 (en) * 2022-11-22 2024-05-29 KRKA, D.D., Novo Mesto Pharmaceutical dosage form of candesartan and indapamide

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161312C (da) 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
TW284688B (es) 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
PL189666B1 (pl) 1998-04-09 2005-09-30 Adamed Sp Z Oo Sposób otrzymywania benzenosulfonianu amlodypiny
HU226642B1 (en) 2001-12-17 2009-05-28 Egis Gyogyszergyar Nyilvanosan Amlodipine bezylate tablets having extended stability and process for producing the same
US20060270715A1 (en) 2003-02-28 2006-11-30 Singh Romi B Dosage forms of amlodipine and processes for their preparation
US20100041644A1 (en) 2006-11-28 2010-02-18 Laboratorios Liconsa, S. A. Stabilized solid pharmaceutical composition of candesartan cilexetil
JP5139515B2 (ja) 2007-04-25 2013-02-06 テバ ファーマシューティカル インダストリーズ リミティド 医薬賦形剤複合体
EP2050440A1 (en) 2007-10-18 2009-04-22 Krka Stable solid pharmaceutical composition comprising candesartan or pharmaceutically acceptable forms thereof
EP2106789A1 (en) 2008-03-31 2009-10-07 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising candesartan
PT2165702E (pt) 2008-09-17 2012-02-07 Helm Ag Composições estáveis e rapidamente dissolvidas de candesartan cilexetil preparadas com granulação húmida
AU2010242308A1 (en) 2009-04-30 2011-12-01 Takeda Pharmaceutical Company Limited Solid preparation
CN101966181A (zh) * 2010-07-08 2011-02-09 王丽燕 包含坎地沙坦和氨氯地平的口服固体制剂及其新应用
CN102743381B (zh) * 2011-04-22 2014-08-27 重庆市力扬医药开发有限公司 一种稳定的坎地沙坦酯氨氯地平药物组合物及其制备方法
CN102764258B (zh) 2011-10-21 2013-09-25 四川百利药业有限责任公司 一种坎地沙坦酯氨氯地平复方片的制备方法
CN102670603B (zh) * 2012-04-29 2017-10-31 浙江华海药业股份有限公司 含有坎地沙坦酯和苯磺酸氨氯地平的口服片剂及其制备方法
CN102688236B (zh) * 2012-06-06 2014-03-26 石药集团中诺药业（石家庄）有限公司 一种坎地沙坦酯氨氯地平片剂组合物及其制备方法

Also Published As

Publication number Publication date
RS58214B1 (sr) 2019-03-29
WO2014097209A1 (en) 2014-06-26
HUE042194T2 (hu) 2019-06-28
EP2934488A1 (en) 2015-10-28
PH12015501301B1 (en) 2015-08-24
HRP20190049T1 (hr) 2019-02-22
PL2934488T3 (pl) 2019-04-30
EA201591097A1 (ru) 2015-10-30
ES2706067T3 (es) 2019-03-27
PL402191A1 (pl) 2014-06-23
PL236001B1 (pl) 2020-11-30
EP2934488B1 (en) 2018-10-17
ZA201505192B (en) 2016-07-27
AU2013365715B2 (en) 2017-10-05
HK1213808A1 (en) 2016-07-15
MY185947A (en) 2021-06-14
UA115257C2 (uk) 2017-10-10
MX374106B (es) 2025-03-05
EA030704B1 (ru) 2018-09-28
BR112015014875A2 (pt) 2017-07-11
AU2013365715A1 (en) 2015-06-18
PH12015501301A1 (en) 2015-08-24
PT2934488T (pt) 2019-01-29
SG11201504473XA (en) 2015-07-30
TR201900350T4 (tr) 2019-02-21

Similar Documents

Publication Publication Date Title
MX2015008032A (es) Una composicion farmaceutica que contiene candesartan cilexetilo y amlodipina.
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
CR20140540A (es) Nueva forma de dosificación y formulación de abediterol
CL2018001510A1 (es) Composición farmacéutica que comprende un potente inhibidor de urat1
ECSP13012467A (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
NZ602442A (en) A fast dissolving pharmaceutical composition
IN2014MN01919A (es)
PH12012502082A1 (en) Combination of active loaded granules with additional actives
CL2014001828A1 (es) Sistema de dosificacion oral de liberacion dual que comprende doxilamina y piridoxina y/o sus analogos, metabolitos y sales de los mismos; forma de dosificacion oral de liberacion dual; kit farmaceutico; uso para aliviar los sintomas de nauseas y vomitos, incluidos los del embarazo.
PH12012502083A1 (en) Manufacturing of active-free granules and tablets comprising the same
CR20110704A (es) Composiciones de dosis fija farmacéuticas sólidas que comprenden irbesartán y amilodipina, su preparación y su aplicación terapéutica
PE20151607A1 (es) Formulaciones de compuestos organicos
BR112014014795A2 (pt) sistema de pélete de multiunidade de liberação imediata
DOP2014000269A (es) Nueva dosificación y formulación
GT201300032A (es) Composicion farmaceutica de liberacion prolongada de trimetazidina
AR080256A1 (es) Formulaciones farmaceuticas solidas de ramipril y besilato de amlodipino y su preparacion
AR100625A1 (es) Formulación de ceritinib
PE20160520A1 (es) Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion
DOP2015000040A (es) Formulación de comprimidos compuestos de dos fases que comprende atorvastatina, irbesartan y carbonato de magnesio
HRP20171930T1 (hr) Analozi diazonamida
BR112014001751A2 (pt) derivados de pirazolina e seu uso como moduladores seletivos do receptor de estrogênio
WO2011126327A3 (en) Pharmaceutical composition with controlled-release properties comprising mosapride or levodropropizine, and preparing method thereof
BR112015022925A2 (pt) partículas de resina de fenilefrina e seu uso em formulações farmacêuticas
MX2015011099A (es) Composiciones farmaceuticas de donepezilo que tienen un perfil de disolución in vitro o parámetros farmacocinéticos específicos.

Legal Events

Date Code Title Description
FG Grant or registration